Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,775 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,499 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,528)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02332512 | Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)(ANSWER) | unknown | Phase 3 | 417 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 24, 2017 | clinicaltrials |
| NCT02613637 | Registry Study on Biological Disease Profile and Clinical Outcome in Patients With Newly Diagnosed or Existent Lung Cancer The LuCa Biology and Outcome (BiO)-Project | unknown | — | 2,000 | University of Ulm |
| 1 |
| Feb 24, 2017 |
| clinicaltrials |
| NCT03060343 | Zeushield Cytotoxic T Lymphocytes (Z-CTLs) for Relapsed or Refractory Non Small Cell Lung Cancer (NSCLC) | unknown | Early Phase 1 | 10 | Yu FengleiOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT03057340 | The Treatment of Advanced Lung Cancer With Dribbles Antigen by Targeting Activation of Tcells | unknown | Phase 1 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Feb 20, 2017 | clinicaltrials |
| NCT02974933 | Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer | unknown | Phase 2 | 48 | Wuling OuOTHER | 1 | Feb 17, 2017 | clinicaltrials |
| NCT03053804 | Clinical Application of MR-PET in Non-small Cell Lung Cancer: Diagnosis, Treatment Outcome, and Prognosis Prediction | unknown | N/A | 75 | National Taiwan University HospitalOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT03053856 | Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients | unknown | Phase 2 | 37 | Samsung Medical CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT03050411 | Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer | unknown | Phase 1 | 30 | Peking University Third HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT03050437 | A Study Comparing Pemetrexed Plus Cisplatin Versus Pemetrexed Alone in NSCLC Patients Who Have Progressed on First Line EGFR-TKI | unknown | Phase 2 | 96 | Samsung Medical CenterOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT03047525 | Study of DC-CTL Combined With CIK for Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 200 | Xiaoyi HuangOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT01714908 | Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21(RECEL) | unknown | Phase 2 | 100 | Jinming YuOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT01744925 | Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT02916459 | EBUS-TBNA vs Flex 19G EBUS-TBNA | unknown | N/A | 250 | Heidelberg UniversityOTHER | 1 | Feb 7, 2017 | clinicaltrials |
| NCT02370017 | Combined Effect of Natural Killer Cell and Doublet Chemotherapy in Advanced NSCLC as the 1st Line Treatment(ANKL-2) | unknown | Phase 2 | 68 | The Catholic University of KoreaOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT02568033 | Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer | unknown | Early Phase 1 | 22 | The Cooper Health SystemOTHER | 1 | Jan 31, 2017 | clinicaltrials |
| NCT03029858 | PD-L1 and Other Immuno-markers Influenced by Osimertinib Treatment in Advanced NSCLC Patients(ATHENE) | unknown | — | 155 | Guangdong Association of Clinical TrialsOTHER | 1 | Jan 24, 2017 | clinicaltrials |
| NCT02988141 | EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC(PRECENT) | unknown | — | 100 | Jianxing HeOTHER | 0 | Jan 20, 2017 | clinicaltrials |
| NCT02851329 | Therapeutic Resistance Prediction of Tyrosine Kinase Inhibitors | unknown | — | 500 | Chinese Academy of SciencesOTHER_GOV | 1 | Jan 19, 2017 | clinicaltrials |
| NCT01885754 | Characterization of Peripheral Muscle Function in Patients With Non-small-cell Lung Cancer | unknown | — | 56 | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de QuebecOTHER | 1 | Jan 6, 2017 | clinicaltrials |
| NCT01887769 | Body Composition Analysis for Patient With Lung Cancer Using Computed Tomography Image Analysis(BAT-SCAN) | unknown | — | 1,000 | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de QuebecOTHER | 1 | Jan 6, 2017 | clinicaltrials |
| NCT02716493 | Feasibility of a 8-week Telerehabilitation Program for Patients With Thoracic Neoplasia Receiving Chemotherapy(TELErp) | unknown | N/A | 5 | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de QuebecOTHER | 1 | Jan 6, 2017 | clinicaltrials |
| NCT03009630 | ENB Guided RFA for Early-stage Peripheral Lung Cancer | unknown | N/A | 50 | Shanghai Chest HospitalOTHER | 1 | Jan 6, 2017 | clinicaltrials |
| NCT03008109 | Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC | unknown | Phase 3 | 80 | Zaiwen FanOTHER_GOV | 0 | Jan 4, 2017 | clinicaltrials |
| NCT03002844 | EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism | unknown | Phase 2 | 50 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Dec 28, 2016 | clinicaltrials |
| NCT02997449 | Complete Endosonographic Intrathoracic Nodal Staging of Lung Cancer Patients in Whom SABR is Considered | unknown | — | 102 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 2 | Dec 20, 2016 | clinicaltrials |
| NCT02029209 | To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer | unknown | Phase 2 / Phase 3 | 110 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 16, 2016 | clinicaltrials |
| NCT02422628 | Correlation Between EGFR Mutation Using cfDNAs and Circulating Tumor Cells in Patients With NSCLC | unknown | — | 400 | National Taiwan University HospitalOTHER | 1 | Dec 14, 2016 | clinicaltrials |
| NCT02839954 | CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02348450 | Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer | unknown | Phase 4 | 308 | Guangdong Association of Clinical TrialsOTHER | 1 | Dec 5, 2016 | clinicaltrials |
| NCT02587689 | Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 20 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 5, 2016 | clinicaltrials |
| NCT02980809 | Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer | unknown | Phase 2 | 60 | First Hospitals affiliated to the China PLA General HospitalOTHER_GOV | 0 | Dec 2, 2016 | clinicaltrials |
| NCT02975609 | Phase II Trial of SBRT Compared With Conventional Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer | unknown | Phase 2 | 100 | Shanghai Chest HospitalOTHER | 1 | Nov 29, 2016 | clinicaltrials |
| NCT02758314 | Evaluation of PD1 / PDL1 Expression on Blood Cells & Tumor Tissue, Their Role as a Prognostic Target in NSCLC Patients | unknown | — | 150 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Nov 25, 2016 | clinicaltrials |
| NCT02787447 | Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy | unknown | Phase 2 | 46 | First People's Hospital of HangzhouOTHER | 1 | Nov 25, 2016 | clinicaltrials |
| NCT02787473 | A Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Docetaxel Consolidation in Patients With Inoperable Squamous Cell Lung Cancer | unknown | Phase 2 | 54 | First People's Hospital of HangzhouOTHER | 1 | Nov 25, 2016 | clinicaltrials |
| NCT02274337 | Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Nov 23, 2016 | clinicaltrials |
| NCT02972320 | Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic | unknown | Phase 2 | 60 | Yunpeng LiuOTHER | 1 | Nov 23, 2016 | clinicaltrials |
| NCT02972333 | Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M | unknown | Phase 3 | 150 | Shandong Cancer Hospital and InstituteOTHER | 0 | Nov 23, 2016 | clinicaltrials |
| NCT02755675 | uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung | unknown | Phase 2 | 120 | Rigshospitalet, DenmarkOTHER | 1 | Nov 21, 2016 | clinicaltrials |
| NCT02505685 | Dynamic PET CT as a Tool for Treatment Efficacy Monitoring in Lung Cancer | unknown | — | 200 | Rabin Medical CenterOTHER | 1 | Nov 18, 2016 | clinicaltrials |
| NCT02960607 | High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC | unknown | Phase 2 | 25 | Chinese Academy of Medical SciencesOTHER | 1 | Nov 18, 2016 | clinicaltrials |
| NCT02961270 | Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation | unknown | Phase 2 | 30 | Chinese Academy of Medical SciencesOTHER | 1 | Nov 11, 2016 | clinicaltrials |
| NCT02951897 | Application of Detecting Circulating Tumor Cells in the Accurate Treatment of Early Stage Lung Adenocarcinoma(CTCs detection) | unknown | N/A | 120 | Third Military Medical UniversityOTHER | 1 | Nov 2, 2016 | clinicaltrials |
| NCT02804100 | Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients | unknown | — | 200 | Wenzhou Medical UniversityOTHER | 1 | Nov 1, 2016 | clinicaltrials |
| NCT02951637 | Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial | unknown | Phase 2 | 300 | Shanghai Chest HospitalOTHER | 0 | Nov 1, 2016 | clinicaltrials |
| NCT02941003 | Precision Diagnosis for Intraoperative Frozen Section of Early Stage Lung Cancer | unknown | N/A | 540 | Shanghai Chest HospitalOTHER | 1 | Oct 27, 2016 | clinicaltrials |
| NCT02946216 | ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC | unknown | — | 200 | First People's Hospital of HangzhouOTHER | 1 | Oct 27, 2016 | clinicaltrials |
| NCT02943798 | Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma | unknown | Phase 2 | 118 | Shanghai Chest HospitalOTHER | 0 | Oct 25, 2016 | clinicaltrials |
| NCT02579564 | Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients | unknown | Phase 3 | 134 | Xinqiao Hospital of ChongqingOTHER | 0 | Oct 21, 2016 | clinicaltrials |
| NCT02938546 | 18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical Study | unknown | Phase 3 | 200 | Shanghai Chest HospitalOTHER | 0 | Oct 21, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Feb 24, 2017source: clinicaltrials